Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study - Concepedia

Concepedia

Publication | Closed Access

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

269

Citations

8

References

2002

Year

Robert T. Schooley, Peter Ruane, Robert A. Myers, Gildon Beall, Harry Lampiris, Daniel Berger, Shanshan Chen, Michael D. Miller, Erica Isaacson, Andrew Cheng

Abstract

In treatment-experienced patients with baseline nucleoside resistance mutations, TDF provided dose-related, durable reductions in HIV-1 RNA. Through 24 weeks, the safety profile of TDF was similar to that of placebo.

References

	Year	Citations

Page 1